TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17385022

Group type: EXPERIMENTAL
Intervention: Intravenous hydrocortisone (HC)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Intravenous dexamethasone (DEX)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Intravenous methylprednisolone (MPL)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Oral prednisolone (PNL)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study: 16351362

Group type: EXPERIMENTAL
Intervention: Upright face orientation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inverted face orientation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Irrelevant faces
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Semantic processing goal
Number of subjects: 0
Study: 11867508

Group type: EXPERIMENTAL
Intervention: Tailored psycho-educational intervention
Number of subjects: 742

Group type: COMPARATOR
Intervention: Untreated control group
Number of subjects: 742
Study: 10215706

Group type: EXPERIMENTAL
Intervention: 6% HES 200/0.5
Number of subjects: 50

Group type: COMPARATOR
Intervention: 5% albumin
Number of subjects: 50
Study: 8537922

Group type: EXPERIMENTAL
Intervention: Existing artificial tooth materials (Group 1)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: New experimental material (Group 2)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Bioform IPN resin teeth (Group 3)
Number of subjects: 67
Study: 1284163

Group type: EXPERIMENTAL
Intervention: gallopamil SR 100 mg twice a day
Number of subjects: 118

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 118
Study: 6142717

Group type: EXPERIMENTAL
Intervention: Liquid oral solution of bromazepam (3 mg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Liquid oral solution of bromazepam (1.5 mg)
Number of subjects: 6
Study: 31540613

Group type: EXPERIMENTAL
Intervention: Treatment for cocaine use disorders (CUD)
Number of subjects: 629
Study: 30088834

Group type: EXPERIMENTAL
Intervention: MBCT + TAU
Number of subjects: 106
Study: 27184297

Group type: EXPERIMENTAL
Intervention: Attention Bias Modification Therapy (ABMT)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control Therapy
Number of subjects: 37
Study: 25348259

Group type: EXPERIMENTAL
Intervention: Stepping Stones Triple P (SSTP)
Number of subjects: 209

Group type: COMPARATOR
Intervention: Care as Usual (CAU)
Number of subjects: 209
Study: 23103033

Group type: EXPERIMENTAL
Intervention: MGuard stent
Number of subjects: 433

Group type: COMPARATOR
Intervention: Control stents (bare metal or drug-eluting)
Number of subjects: 433
Study: 20840318

Group type: EXPERIMENTAL
Intervention: Zibotentan 15 mg
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: Zibotentan 10 mg
Number of subjects: 312

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 312
Study: 17880872

Group type: EXPERIMENTAL
Intervention: Intralesional autologous blood injection
Number of subjects: 64

Group type: COMPARATOR
Intervention: Corticosteroid injection
Number of subjects: 64
Study: 16115973

Group type: EXPERIMENTAL
Intervention: Fentanyl injection over 2 seconds
Number of subjects: 450

Group type: COMPARATOR
Intervention: Fentanyl injection over 15 seconds
Number of subjects: 450

Group type: COMPARATOR
Intervention: Fentanyl injection over 30 seconds
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Light smoking (<10 cigarettes per day)
Number of subjects: 450
Study: 12107308

Group type: EXPERIMENTAL
Intervention: Single-portal endoscopic carpal tunnel release
Number of subjects: 147

Group type: COMPARATOR
Intervention: Open carpal tunnel release
Number of subjects: 147
Study: 9144753

Group type: EXPERIMENTAL
Intervention: Brief, behaviorally based counseling by physicians, plus a telephone follow‐up 2 weeks later
Number of subjects: 255

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 255
Study: 7957497

Group type: EXPERIMENTAL
Intervention: rhEPO (500 U kg‐1 body weight twice weekly during a 3 week period)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group (no rhEPO)
Number of subjects: 62
Study: 3669729

Group type: EXPERIMENTAL
Intervention: MgSO4 inhalation
Number of subjects: 16

Group type: COMPARATOR
Intervention: NaCl (saline)
Number of subjects: 16
Study: 31960624

Group type: EXPERIMENTAL
Intervention: Tezepelumab 35 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Tezepelumab 105 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Tezepelumab 280 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Tezepelumab (all doses)
Number of subjects: 24
Study: 30126411

Group type: EXPERIMENTAL
Intervention: Micro-level components of the physical HIV risk environment in Ciudad Juarez
Number of subjects: 584

Group type: EXPERIMENTAL
Intervention: Micro-level components of the physical HIV risk environment in Tijuana
Number of subjects: 584
Study: 27765357

Group type: EXPERIMENTAL
Intervention: Lecithin-formulated Boswellia extract (CSP)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Non-formulated Boswellia extract (BE)
Number of subjects: 12
Study: 23825183

Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP)
Number of subjects: 230

Group type: COMPARATOR
Intervention: Active control
Number of subjects: 230
Study: 22538140

Group type: EXPERIMENTAL
Intervention: Self-care video messages from diabetes nurse practitioner
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Self-care video messages from diabetes nurse practitioner (viewed >10 a month)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 65
Study: 20864916

Group type: EXPERIMENTAL
Intervention: Modified FOLFOX6 (oxaliplatin 85 mg/m², leucovorin 350 mg, and 5-fluorouracil 400 mg/m² bolus; 2.4 g/m² infusion, 46 h) day 1; bevacizumab 5 mg/kg on day 1; cetuximab 400 mg/m² on day 1, then 250 mg/m² on days 1 and 8, every 14 days until progressive disease (PD)
Number of subjects: 31
Study: 18311567

Group type: EXPERIMENTAL
Intervention: Aspheric ablation profiles developed based on individual wavefront data and standardized correction profiles.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional spheric ablation profiles.
Number of subjects: 0
Study: 14644790

Group type: EXPERIMENTAL
Intervention: Personal counseling session and signed contract promising to wear bicycle helmets; helmet fitting for 57 children who did not own helmets
Number of subjects: 222

Group type: COMPARATOR
Intervention: Control group received a photocopied photograph of the hospital
Number of subjects: 222
Study: 11775238

Group type: EXPERIMENTAL
Intervention: Recombinant bovine basic fibroblast growth factor (rbFGF) 150 AU/cm2/day
Number of subjects: 1024

Group type: COMPARATOR
Intervention: Placebo (vehicle without rbFGF)
Number of subjects: 1024

Group type: EXPERIMENTAL
Intervention: Recombinant bovine basic fibroblast growth factor (rbFGF)
Number of subjects: 1024

Group type: COMPARATOR
Intervention: Control (the patients themselves)
Number of subjects: 1024
Study: 8977914

Group type: EXPERIMENTAL
Intervention: Calcium carbasalate (equivalent to aspirin 325 mg daily, single dose 6 hours post-operation, repeated for 7 days)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Calcium carbasalate
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56

Group type: COMPARATOR
Intervention: Calcium carbasalate and Placebo
Number of subjects: 56
Study: 1587379

Group type: EXPERIMENTAL
Intervention: 25 micrograms 17 beta-estradiol (Vagifem) administered as a vaginal tablet, treated once daily for 2 weeks and twice a week for 10 weeks
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: 25 micrograms 17 beta-estradiol (Vagifem)
Number of subjects: 164

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 164
Study: 4025944

Group type: EXPERIMENTAL
Intervention: Activated Partial Thromboplastin Time (APTT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Howel Time (HT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Both APTT and HT
Number of subjects: 0
Study: 31645444

Group type: EXPERIMENTAL
Intervention: Adenovirus Type 5-Based HIV-1 Vaccines
Number of subjects: 0
Study: 29517132

Group type: EXPERIMENTAL
Intervention: AZD5718
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 26881270

Group type: EXPERIMENTAL
Intervention: Assessment of infants' problems
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Carer's level of concern
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Child's engagement in cognitive tasks
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Holistic assessment
Number of subjects: 70
Study: 24059649

Group type: EXPERIMENTAL
Intervention: Inulin (10 g/d for 8 weeks)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Maltodextrin (control group)
Number of subjects: 49
Study: 22291886

Group type: EXPERIMENTAL
Intervention: Clonidine 150 µg orally
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clonidine 75 µg orally
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clonidine 0 µg (placebo)
Number of subjects: 0
Study: 20502388

Group type: EXPERIMENTAL
Intervention: Alcohol-positive adolescents scoring at or above the clinical cutoff on the ADI (n = 45)
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Alcohol-positive adolescents scoring below the clinical cutoff on the ADI (n = 68)
Number of subjects: 177

Group type: COMPARATOR
Intervention: Alcohol-negative adolescents (n = 64)
Number of subjects: 177
Study: 18349316

Group type: EXPERIMENTAL
Intervention: Irradiation stent group (self-expandable esophageal stent loaded with 125I seeds)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control group (conventional self-expandable covered stent)
Number of subjects: 53
Study: 16362593

Group type: EXPERIMENTAL
Intervention: Intranasal desmopressin 1x 20 microg for 2 months
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Conditioning therapy for 2 months
Number of subjects: 55

Group type: COMPARATOR
Intervention: Intranasal isotonic solutions (placebo)
Number of subjects: 55
Study: 12358166

Group type: EXPERIMENTAL
Intervention: Cooled RF
Number of subjects: 59

Group type: COMPARATOR
Intervention: Standard RF
Number of subjects: 59
Study: 10073511

Group type: EXPERIMENTAL
Intervention: 600 mg mifepristone
Number of subjects: 1717

Group type: EXPERIMENTAL
Intervention: 50 mg mifepristone
Number of subjects: 1717

Group type: EXPERIMENTAL
Intervention: 10 mg mifepristone
Number of subjects: 1717

Group type: EXPERIMENTAL
Intervention: mifepristone (all doses)
Number of subjects: 1717
Study: 7579847

Group type: EXPERIMENTAL
Intervention: Retrograde warm blood cardioplegia
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antegrade warm blood cardioplegia
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cold oxygenated crystalloid cardioplegia
Number of subjects: 0

Group type: COMPARATOR
Intervention: Antegrade cold blood cardioplegia
Number of subjects: 0
Study: 2149565

Group type: EXPERIMENTAL
Intervention: Trazodone hydrochloride (average dose 201 mg)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo (average dose 238 mg)
Number of subjects: 42
Study: 484765

Group type: EXPERIMENTAL
Intervention: Special Intervention (SI)
Number of subjects: 616

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 616
Study: 31423117

Group type: EXPERIMENTAL
Intervention: Single Sign-On (SSO) implementation
Number of subjects: 19
Study: 28724652

Group type: EXPERIMENTAL
Intervention: Admission bradycardia (AHR <60 beats per minute)
Number of subjects: 1460

Group type: EXPERIMENTAL
Intervention: Admission tachycardia (AHR >100 beats per minute)
Number of subjects: 1460
Study: 24990200

Group type: EXPERIMENTAL
Intervention: 5-mg once-daily tadalafil
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: 5-mg alternate-day tadalafil
Number of subjects: 144
Study: 24640150

Group type: EXPERIMENTAL
Intervention: Reamberin
Number of subjects: 257

Group type: COMPARATOR
Intervention: Chemotherapeutics alone
Number of subjects: 257
Study: 21078200

Group type: EXPERIMENTAL
Intervention: SHED‐IT Resources (provision of materials including DVD, handbooks, pedometer, tape measure)
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: SHED‐IT Online (same materials as SHED‐IT Resources plus access to and instruction on how to use the study website)
Number of subjects: 159

Group type: COMPARATOR
Intervention: Wait-list Control
Number of subjects: 159
Study: 18251638

Group type: COMPARATOR
Intervention: Toothbrush alone
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Toothbrush + unwaxed floss
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Toothbrush + woven floss
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Toothbrush + shred-resistant floss
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Toothbrush + powered flosser
Number of subjects: 25
Study: 16830130

Group type: EXPERIMENTAL
Intervention: MDMA 0 mg with alcohol
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: MDMA 75 mg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: MDMA 100 mg
Number of subjects: 18

Group type: COMPARATOR
Intervention: Alcohol alone
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: MDMA with alcohol
Number of subjects: 18
Study: 14550442

Group type: EXPERIMENTAL
Intervention: Diet low in fat and high in fiber, fruits, and vegetables
Number of subjects: 1197

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 1197
Study: 10997956

Group type: EXPERIMENTAL
Intervention: Carbohydrate supplementation (1.0 g CHO.kg body mass(‐1) prior to and 0.5 g CHO.kg body mass(‐1) every 10 minutes during IRT)
Number of subjects: 8
Study: 9116176

Group type: EXPERIMENTAL
Intervention: CDR Cognitive Assessment System
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: RBAD
Number of subjects: 45

Group type: COMPARATOR
Intervention: Mattis Dementia Rating Scale
Number of subjects: 45

Group type: COMPARATOR
Intervention: Mini‐Mental State Examination
Number of subjects: 45

Group type: COMPARATOR
Intervention: Wechsler Memory Scale‐Revised
Number of subjects: 45

Group type: COMPARATOR
Intervention: Alzheimer's Disease Assessment Scale‐Cognitive Subscale
Number of subjects: 45

Group type: COMPARATOR
Intervention: Repeatable Battery for the Assessment of Dementia (RBAD)
Number of subjects: 45
Study: 2002211

Group type: EXPERIMENTAL
Intervention: Methylphenidate 0.15 mg/kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Methylphenidate 0.3 mg/kg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 6338721

Group type: EXPERIMENTAL
Intervention: Breast stimulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 30365254

Group type: EXPERIMENTAL
Intervention: TEAS+TAP
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: TAP
Number of subjects: 101

Group type: COMPARATOR
Intervention: Control
Number of subjects: 101
Study: 27059469

Group type: EXPERIMENTAL
Intervention: In-bed leg cycling (30 minutes, 5 days per week, for up to 28 days) in addition to routine physiotherapy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Routine physiotherapy alone
Number of subjects: 60
Study: 26261114

Group type: EXPERIMENTAL
Intervention: Active learning modules (case scenarios, critical appraisal of prescriptions, drug identification)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Conventional tutorial mode
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Active learning sessions
Number of subjects: 90

Group type: COMPARATOR
Intervention: Tutorial group
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Overall preference
Number of subjects: 90
Study: 23651425

Group type: EXPERIMENTAL
Intervention: Intramuscular testosterone undecanoate (1000 mg)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 21908265

Group type: EXPERIMENTAL
Intervention: Risk estimates with no decimal places
Number of subjects: 3422

Group type: COMPARATOR
Intervention: Risk estimates with decimal places (1, 2, 3 decimals)
Number of subjects: 3422

Group type: EXPERIMENTAL
Intervention: Risk estimates with zero decimals
Number of subjects: 3422

Group type: COMPARATOR
Intervention: One decimal place
Number of subjects: 3422

Group type: COMPARATOR
Intervention: Two decimal places
Number of subjects: 3422

Group type: COMPARATOR
Intervention: Three decimal places
Number of subjects: 3422
Study: 18979716

Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: New therapies under preclinical investigation or early stage clinical trials
Number of subjects: 0
Study: 16554579

Group type: EXPERIMENTAL
Intervention: Mangafodipir trisodium-enhanced MRI
Number of subjects: 41

Group type: COMPARATOR
Intervention: Ferucarbotran-enhanced MRI
Number of subjects: 41
Study: 14570682

Group type: EXPERIMENTAL
Intervention: Tidal volume breathing after maximal exhalation
Number of subjects: 23

Group type: COMPARATOR
Intervention: Tidal volume breathing alone
Number of subjects: 23
Study: 10764418

Group type: EXPERIMENTAL
Intervention: Healthy humans (n=11)
Number of subjects: 22

Group type: COMPARATOR
Intervention: CHF patients (n=11)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Norepinephrine (10 micromol/L) exposure in isolated cardiomyocytes
Number of subjects: 22
Study: 8650928

Group type: EXPERIMENTAL
Intervention: Wobenzym (enzyme therapy)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Lynestrenol (hormone therapy)
Number of subjects: 29
Study: 1611639

Group type: EXPERIMENTAL
Intervention: Diltiazem 180 mg, 360 mg, and 540 mg once daily for two weeks
Number of subjects: 107

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 107
Study: 6146045

Group type: EXPERIMENTAL
Intervention: 200,000 IU of vitamin A given once every 6 months
Number of subjects: 50000

Group type: COMPARATOR
Intervention: Control areas (no vitamin A supplementation)
Number of subjects: 50000

Group type: COMPARATOR
Intervention: Children not receiving vitamin A supplements (case-control analysis)
Number of subjects: 50000
Study: 30082107

Group type: EXPERIMENTAL
Intervention: Variably Occluded Face Mask (VOFM)
Number of subjects: 0
Study: 29356207

Group type: EXPERIMENTAL
Intervention: Adjunctive mexiletine therapy
Number of subjects: 259

Group type: COMPARATOR
Intervention: Catheter ablation
Number of subjects: 259
Study: 27021829

Group type: EXPERIMENTAL
Intervention: Parent involvement intervention (weekly newsletters and text messages for 5 weeks)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 42
Study: 24060708

Group type: EXPERIMENTAL
Intervention: Intensive interdisciplinary pain treatment (IIPT)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Waiting-list control group (WCG)
Number of subjects: 104
Study: 22488252

Group type: EXPERIMENTAL
Intervention: Fluoride-supplemented milk (200 ml with 5 mg F/l as NaF once a day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Unsupplemented milk (200 ml)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No milk consumption
Number of subjects: 0
Study: 20884063

Group type: EXPERIMENTAL
Intervention: Quetiapine XR 150mg/day
Number of subjects: 919

Group type: EXPERIMENTAL
Intervention: Quetiapine XR 300mg/day
Number of subjects: 919

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 919
Study: 18633021

Group type: EXPERIMENTAL
Intervention: Palonosetron 0.075 mg
Number of subjects: 544

Group type: EXPERIMENTAL
Intervention: Palonosetron 0.025 mg
Number of subjects: 544

Group type: EXPERIMENTAL
Intervention: Palonosetron 0.050 mg
Number of subjects: 544

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 544
Study: 16822125

Group type: EXPERIMENTAL
Intervention: Invariant approach
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Heuristic approach
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Exemplar-based approach
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multiple strategies
Number of subjects: 0
Study: 12819656

Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside (SNP) in the upright position
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Acetylcholine (Ach) in the upright position
Number of subjects: 53
Study: 11027904

Group type: EXPERIMENTAL
Intervention: Hydromorphone 2 mg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Ketorolac 10 mg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 8676034

Group type: EXPERIMENTAL
Intervention: Shortened postoperative mobilization programme (full activity allowed after 8 weeks)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Standard postoperative mobilization programme (unrestricted use not allowed until 10 weeks)
Number of subjects: 82
Study: 2066455

Group type: EXPERIMENTAL
Intervention: High-dose fluoxetine (median 80 mg/day)
Number of subjects: 706

Group type: EXPERIMENTAL
Intervention: Standard-dose imipramine (median 200 mg/day)
Number of subjects: 706

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 706
Study: 6190888

Group type: EXPERIMENTAL
Intervention: Intravenous metronidazole alone
Number of subjects: 100

Group type: COMPARATOR
Intervention: Combination of metronidazole and gentamicin
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Quality of bowel preparation (poor)
Number of subjects: 100
Study: 29505321

Group type: EXPERIMENTAL
Intervention: Home Exercise Program (HEP) consisting of three static balance exercises: feet-together, single-leg stance, and tandem, performed twice for 30-60 seconds, once per day, 3 days per week for 12 weeks.
Number of subjects: 6

Group type: COMPARATOR
Intervention: No Home Exercise Program (No HEP)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Healthy Control Group (HCG)
Number of subjects: 6
Study: 30138021

Group type: EXPERIMENTAL
Intervention: Couple-based physical activity intervention (4 videoconference sessions including training in communication and support skills and behavior change techniques)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 20
Study: 24832388

Group type: EXPERIMENTAL
Intervention: 1.0 μg/kg fentanyl (group F)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: 0.5 μg/kg dexmedetomidine (group D0.5)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: 1.0 μg/kg dexmedetomidine (group D1.0)
Number of subjects: 66
Study: 24185044

Group type: EXPERIMENTAL
Intervention: Raltegravir + Tenofovir/Emtricitabine + Maraviroc (MVC), n=15
Number of subjects: 30

Group type: COMPARATOR
Intervention: Raltegravir + Tenofovir/Emtricitabine (Control), n=15
Number of subjects: 30
Study: 22260359

Group type: EXPERIMENTAL
Intervention: Alcohol-dosed participants
Number of subjects: 101

Group type: COMPARATOR
Intervention: Placebo (non-alcoholic drink)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Control (diluted orange cordial)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Alcohol-dosed females
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: All conditions
Number of subjects: 101